FINWIRES · TerminalLIVE
FINWIRES

LSI Industries Fiscal Q3 Adjusted EPS, Sales Rise; Shares Up Pre-Bell

-- LSI Industries (LYTS) reported fiscal third-quarter adjusted earnings Thursday of $0.28 per diluted share, up from $0.20 a year earlier.

Three analysts polled by FactSet expected $0.18.

Net sales for the quarter ended March 31 were $150.5 million, up from $132.5 million a year earlier.

Three analysts surveyed by FactSet expected $138.7 million.

The company maintained its quarterly dividend at $0.05 a share, payable May 12 to holders of record on May 4.

Shares of the company rose 6.2% in Thursday premarket trading.

Related Articles

Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Ibm Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our price target by $37 to $296, 23x our 2026 EPS view, above IBM's three-year average (~20x) on AI tailwinds and growing software exposure. We raise our 2026 EPS view by $0.07 to $12.86 and lift 2027's by $0.03 to $13.90. Q1 results offered a mixed response to the AI competition threat. Bears will focus on Software growth (ex-FX) decelerating to 8% from 11% in Q4 with the segment's 2026 outlook improving only slightly to 10%+ from 10% despite the Confluent acquisition closing early (providing a ~50-bp Software growth boost). Some analysts expected more out of Consulting and will point to its modest 1% sales growth as indicative of COBOL modernization pressure from emerging AI tools. We take a more bullish stance and see Consulting results as resilient, with sales/signings both growing despite ongoing macroeconomic pressures and 2026 growth still forecasted near 5%. On the Software side, ARR again grew 10% Y/Y (consistent with prior periods) and Red Hat encouragingly rebounded to 10% from 8% in Q4.

$IBM
Australia

Regeneron Says FDA Granted Accelerated Approval for Genetic Hearing Loss Therapy

Regeneron (REGN) said Thursday that the US Food and Drug Administration has granted accelerated approval for Otarmeni therapy indicated for the treatment of pediatric and adult patients with OTOF gene-related hearing loss.FDA's approval was based on the ongoing Chord trial that showed 16 of 20 participants experienced hearing improvements per pure tone audiometry assessments, while 14 out of 20 demonstrated an auditory brainstem response, according to a statement.Otarmeni's continued approval may be contingent upon verification and description of clinical benefit in the confirmatory portion of the Chord trial, Regeneron said.The company said it will provide Otarmeni at no cost to clinically eligible individuals in the US.Shares of the company were up 2% in Thursday trading.Price: $761.47, Change: $+14.89, Percent Change: +1.99%

$REGN
Sectors

Sector Update: Health Care

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) fell 1.9%.In corporate news, Thermo Fisher Scientific (TMO) raised its full-year outlook on Thursday as Q1 results came in stronger than expected, even as organic growth fell short of analysts' estimates. Its shares fell 10.9%.

$TMO